Our study results suggest that AdipoRon may be a promising drug for the restoration of diabetic nephropathy by reducing lipotoxicity through the activation of adiponectin receptors and downstream targets through stimulation of the intracellular Ca2+/AMPK-LKB1/PPARα pathway and also by increasing ceramidase activity [24,25]. The gene discussed is PPARA; the disease is diabetic kidney disease.